News

This is the second Zealand-developed gap junction modifier, known as ZP1609 (GAP-134), that Wyeth has advanced into clinical trials. ZP1609 has shown pharmacological effects in animal models of

Under the terms of the agreement, the companies will share responsibility for development and commercialization of the oxidative stress inducer, STA-4783, in the US. GlaxoSmithKline (GSK) will have

Adventrx markets vinorelbine tartrate as Navelbine, but is developing ANX-530 as an emulsion formulation, designed to reduce the incidence and severity of vein irritation from IV-delivery of the

After the merger, Dara stockholders will hold 96.4% of Point’s outstanding shares of common stock on a fully-diluted basis, and Point will change its name to Dara BioSciences,

The primary objective is to evaluate overall survival in glioma patients receiving the vaccination. The trial is designed to enroll approximately 30 patients with recurrent high-grade glioma. Patients

The data safety monitoring board (DSMB) observed a continued acceptable safety profile, and evidence of a consistent pharmacological effect of its Phase II drug, VIA-2291. Dr Adeoye Olukotun,

A total of 17 patients were enrolled for the Phase I study. Asymptomatic hypokalemia was the only dose limiting toxicity (DLT) observed. Analysis of the data showed an

The data from this Phase II clinical study, which is still being analyzed, shows that the vaccine was immunogenic and met the predefined criterion of an overall immune

This study will be conducted in approximately 24 patients chronically infected with hepatitis C virus infection (HCV) and human immunodeficiency virus (HIV). Patient cohorts will receive ascending dose